4. In vitro activity of imipenem/relebactam against carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa isolates
Main Article Content
Abstract
38 strains of Klebsiella pneumoniae producing class A carbapenemase and 42 strains of Pseudomonas aeruginosa producing class A carbapenemase or carbapenem-resistant non- carbapenemase producing were isolated at Bach Mai Hospital in 2024; Etest method were used to determine their imipenem/relebactam minimum inhibitory concentration (MIC) values. The results showed the susceptibility rates to imipenem/relebactam were 92.1% (MIC50 = MIC90 = 0.5 µg/ml) and 21.4% (MIC50 = MIC90 > 32 µg/ml) for K. pneumoniae strains and for P. aeruginosa strains, respectively. Therefore, imipenem/relebactam could be an option to consider for treatment of infections caused by carbapenem-resistant K. pneumoniae and P. aeruginosa; we suggest it should be used only after obtaining antibiotic susceptibility results.
Article Details
Keywords
Klebsiella pneumoniae, Pseudomonas aeruginosa, imipenem/relebactam
References
1. World Health Organization. Antimicrobial resistance. Fact sheet. Published 2018. Accessed 2023. www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. 2023.
2. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis. 2017;15(65):644-652. doi.org/10.1093/cid/cix4 11.
3. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;(18):318-327. doi.org/10.1016/S1473-3099(17)30753-3.
4. Yahav D, Giske CG, Graamatniece A, et al. New β-lactam- β-lactamase inhibitor combinations. Clin Microbiol Rev. 2021;34(1):e00115-20. doi.org/10.1128/CMR.0 0115-20.
5. Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4):e00031-19. doi: 10. 1128/CMR.00031-19.
6. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41:252-275. doi.org/10.1093/FEMSRE/FUX013
7. Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873-5884. doi.org/10.1 128/AAC.01019-15.
8. Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Update. 2019;44:100640. doi.org/10.1016/j.drup.2019.07.002.
9. Trần Hải Yến, Phạm Hồng Nhung, Nguyễn Tuấn Linh. Phân loại carbapenemase và kiểu cách đề kháng của chủng Klebsiella kháng carbapenem. Tạp chí Y học lâm sàng. 2020;119:115-120.
10. Nguyễn Tuấn Linh, Phạm Hồng Nhung, Trần Minh Châu. Nghiên cứu kiểu hình carbapenemase và tình hình đề kháng kháng sinh của các chủng Enterobacteriaceae kháng carbapenem. Tạp chí Y học lâm sàng. 2020;116:53-59.
11. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976. doi.org/ 10.1128/AAC.01009-09.
12. MERCK. nonymous. Highlights of prescribing information. RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, for intravenous use. Published 2019. www.merck.com/product/usa/pi_circulars/r/rec arbrio/recarbrio_pi.pdf.
13. Janet A Hindler, Patricia J Simner, April Abbott, et al. Analysis and Presentation of cumulative antimicrobial susceptibility test data. 5th ed. CLSI guideline M39. Clinical and Laboratory Standards Institute. 2022.
14. James S Lewis II, Amy J Mathers, April M Bobenchik. Performance Standards for antimicrobial susceptibility testing. 34th Ed. CLSI suplement M100. Clinical and Laboratory Standards Institute. 2024.
15. Delgado-Valverde M, Portillo-Calderon I, Alcalde-Rico M, et al. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2024;43:445-457. /doi.org/10.1007/s10096-023-04735
16. Mashaly ME, Mashaly GE. Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechnisms of imipenem non-susceptibility. Iran J Microbiol. 2021;13:785-792.
17. Ding L, Shen S, Chen J, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Cli Microbial Rev. 2023;36(4):e0000823. doi.org/10.1128/cmr.000 08-23.
18. Haidar G, Alkround A, Cheng S, et al. Association between the presence of aminoglycoside-modifing enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and Extended-spectrum- β-lactamase-producing Enterocbacter species. Antimicrob Agents Chemother. 2016;60(9):5208-14. doi.org/10.1128/aac.0086 9-16
19. Bonnin RA, Bernabeu A, Emeraud C, et al. In vitro activity of imipenem-relebatcam, meropenem-vabobactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics. 2023;6:12:102. doi: 10.3390/antibiotics12010102.
20. Zhang H, Jia P, Zhu Y, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist. 2021;14:3509-3518. doi. org/ 10. 2147/ IDR. S3255 20.
2. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis. 2017;15(65):644-652. doi.org/10.1093/cid/cix4 11.
3. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;(18):318-327. doi.org/10.1016/S1473-3099(17)30753-3.
4. Yahav D, Giske CG, Graamatniece A, et al. New β-lactam- β-lactamase inhibitor combinations. Clin Microbiol Rev. 2021;34(1):e00115-20. doi.org/10.1128/CMR.0 0115-20.
5. Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4):e00031-19. doi: 10. 1128/CMR.00031-19.
6. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41:252-275. doi.org/10.1093/FEMSRE/FUX013
7. Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873-5884. doi.org/10.1 128/AAC.01019-15.
8. Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Update. 2019;44:100640. doi.org/10.1016/j.drup.2019.07.002.
9. Trần Hải Yến, Phạm Hồng Nhung, Nguyễn Tuấn Linh. Phân loại carbapenemase và kiểu cách đề kháng của chủng Klebsiella kháng carbapenem. Tạp chí Y học lâm sàng. 2020;119:115-120.
10. Nguyễn Tuấn Linh, Phạm Hồng Nhung, Trần Minh Châu. Nghiên cứu kiểu hình carbapenemase và tình hình đề kháng kháng sinh của các chủng Enterobacteriaceae kháng carbapenem. Tạp chí Y học lâm sàng. 2020;116:53-59.
11. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976. doi.org/ 10.1128/AAC.01009-09.
12. MERCK. nonymous. Highlights of prescribing information. RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, for intravenous use. Published 2019. www.merck.com/product/usa/pi_circulars/r/rec arbrio/recarbrio_pi.pdf.
13. Janet A Hindler, Patricia J Simner, April Abbott, et al. Analysis and Presentation of cumulative antimicrobial susceptibility test data. 5th ed. CLSI guideline M39. Clinical and Laboratory Standards Institute. 2022.
14. James S Lewis II, Amy J Mathers, April M Bobenchik. Performance Standards for antimicrobial susceptibility testing. 34th Ed. CLSI suplement M100. Clinical and Laboratory Standards Institute. 2024.
15. Delgado-Valverde M, Portillo-Calderon I, Alcalde-Rico M, et al. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2024;43:445-457. /doi.org/10.1007/s10096-023-04735
16. Mashaly ME, Mashaly GE. Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechnisms of imipenem non-susceptibility. Iran J Microbiol. 2021;13:785-792.
17. Ding L, Shen S, Chen J, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Cli Microbial Rev. 2023;36(4):e0000823. doi.org/10.1128/cmr.000 08-23.
18. Haidar G, Alkround A, Cheng S, et al. Association between the presence of aminoglycoside-modifing enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and Extended-spectrum- β-lactamase-producing Enterocbacter species. Antimicrob Agents Chemother. 2016;60(9):5208-14. doi.org/10.1128/aac.0086 9-16
19. Bonnin RA, Bernabeu A, Emeraud C, et al. In vitro activity of imipenem-relebatcam, meropenem-vabobactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics. 2023;6:12:102. doi: 10.3390/antibiotics12010102.
20. Zhang H, Jia P, Zhu Y, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist. 2021;14:3509-3518. doi. org/ 10. 2147/ IDR. S3255 20.